Pencla Duo Use In Pregnancy & Lactation

Pregnancy: Animal studies do not indicate direct/indirect harmful effects in pregnancy, embryonal/foetal development, parturition or postnatal development. Limited data on the use of Co-Amoxiclav during pregnancy in humans does not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane, it was reported that prophylactic treatment with Co-Amoxiclav may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.
Lactation: Both substances are excreted into the breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes may be possible in the breast-fed infant, so that breast-feeding might have to be discontinued. The possibility of sensitisation should be taken into account. Co-Amoxiclav should only be used during breast-feeding if the doctor considers the benefit/risk assessment to the infant.